Introduction
============

The use of different combinations of anthropometric indices has been shown to produce substantially different proportions of subjects at increased health risks.[@b1-dmso-6-403] Body mass index (BMI), as an index of general adiposity, and several indices of abdominal obesity, such as waist circumference (WC) and waist-to-hip ratio (WHR), are associated with increased cardiometabolic risk and risk of death. Several meta-analyses have failed to prove substantial superiority of abdominal obesity indices over BMI or between the two aforementioned abdominal obesity indices.[@b2-dmso-6-403]--[@b4-dmso-6-403]

Since the mid-1990s, waist-to-height ratio (WHtR) has emerged as a promising index for identification of subjects at increased cardiometabolic risk in both adults[@b5-dmso-6-403]--[@b7-dmso-6-403] and children.[@b8-dmso-6-403],[@b9-dmso-6-403] A huge number of studies have been undertaken since then in order to evaluate the ability of this index in comparison to BMI and other indices to identify healthy humans at increased cardiometabolic risk. It has been suggested that WHtR has several advantages compared to BMI, and even to WC and WHR, as a simple and rapid screening tool, including its ability to identify health risks in both males and females, in different ethnic groups, and in all age groups, including adults and children.[@b10-dmso-6-403] Moreover, it has been proposed that a cutoff value of 0.5 for both men and women and individuals of Caucasian, Asian, and Central American origin can be used for the prediction of cardiometabolic risk. This value was the mean value of the suggested boundary values regarding several cardiovascular disease (CVD) risk factors.[@b11-dmso-6-403] This cutoff has been used to support the simple public health message "keep your waist circumference to less than half your height."[@b11-dmso-6-403]

Several meta-analyses have aimed to put together the results from studies highlighting the usefulness of WHtR compared to BMI and other body fatness indices to identify cardiometabolic risk in healthy adults[@b12-dmso-6-403]--[@b15-dmso-6-403] and children.[@b16-dmso-6-403] Barzi et al concluded that no single index among BMI, WHtR, WC, and WHR is superior than any other in detecting dyslipidemia in both Asian and non-Asian populations.[@b13-dmso-6-403] In the meta-analysis of van Dijk et al,[@b15-dmso-6-403] WC was proposed as superior in detecting single CVD risk factors compared to BMI, WHtR, and WHR, but this meta-analysis used only correlation coefficients for their conclusions. Kodama et al showed that WHtR had a stronger association with incident diabetes than BMI and WHR.[@b14-dmso-6-403] Ashwell et al showed that WHtR had a better discriminatory power than BMI and WC in detecting several cardiometabolic risk factors.[@b12-dmso-6-403] This latter meta-analysis used pooled area-under-the-curve values but included both cross-sectional and prospective studies in the same models.

The aim of the present meta-analysis, therefore, was to compare the ability of WHtR and BMI to detect multiple cardiometabolic risks and mortality, both cross-sectionally and prospectively, using reported optimal cutoffs for these indices.

Methods
=======

Data sources and search strategy
--------------------------------

A literature search was performed using Pubmed and Embase databases through May 9, 2013 using the terms ("waist-to-height ratio" OR "waist/height ratio" OR "stature-to-height ratio" OR "stature/height ratio" OR "WHtR" OR "WSR") AND ("body mass index" OR "BMI"). Only original full-text studies written in English were selected for analysis. Conference abstracts were excluded since presented information was limited for data extraction.

Inclusion criteria
------------------

-   Adults older than 18 years, irrespective of sex and ethnic background

-   Cross-sectional or prospective studies

-   Studies reporting associations between at least one of the primary outcomes and both anthropometric indices, ie, exposure measures BMI and WHtR

-   For cross-sectional studies, only those reporting optimal BMI and WHtR cutoffs

-   Studies from which 2 × 2 tables could be retrieved (outcome present/absent, exposure positive/negative).

Exclusion criteria
------------------

-   Case-control studies

-   Studies evaluating cardiometabolic risk in specific high-risk groups (eg, patients undergoing coronary angiography)

-   Studies reporting on single lipid abnormality or single systolic or diastolic hypertension

-   Studies with children and/or adolescents.

Primary outcomes
----------------

Primary outcomes for cross-sectional studies were defined as follows:

1.  Diabetes mellitus (DM). Any combination of fasting blood glucose ≥7.0 mmol/L (≥126 mg/dL) or 2-hour post-challenge blood glucose ≥11.1 mmol/L (≥200 mg/dL) or patients with physician diagnosis of diabetes or patients receiving anti-diabetic medication.

2.  Elevated blood pressure. Any combination of systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg and/or patients with physician diagnosis of hypertension and/or patients receiving anti-hypertensive medication.

3.  Dyslipidemia. Treatment for dyslipidemia or two or more abnormal serum lipid measurements including total cholesterol ≥5.2 mmol/L (≥200 mg/dL), low-density-lipoprotein cholesterol ≥3.5 mmol/L (≥135 mg/dL), triglycerides ≥1.7 mmol/L (≥150 mg/dL), or high-density-lipoprotein cholesterol \<1.03 mmol/L (\<40 mg/dL).

4.  Metabolic syndrome (MetS). Two or more risk factors according to International Diabetes Federation or American Heart Association criteria when WC was not included in the definition (ie, two or more criteria out of four), or three or more criteria when WC was included in the criteria (ie, three or more criteria out of five).

Regarding prospective studies, primary outcomes were: all-cause mortality; CVD mortality; incident CVD including myocardial infarction and stroke; and incident DM using the same cutoffs as described previously.

Exposure cutoffs selection
--------------------------

The search of the identified studies revealed that reporting of exposure cutoffs was based on three different methods by the researchers: optimal cutoffs, ie, cutoffs that were chosen in order to maximize sensitivity and specificity of the indices; standard cutoffs, ie, selection of 25 kg/m^2^ for non-Asians or 23 kg/m^2^ for Asians for BMI cutoffs and of 0.5 for WHtR cutoffs; and cutoffs based on percentiles, ie, data were split in quartiles, quintiles, and so forth. We initially aimed to evaluate the discriminative ability of standard BMI and WHtR cutoffs in detecting cardiometabolic risk. However, this task proved difficult because of the limited number of studies that presented findings in a way that data could be extracted for meta-analysis. Therefore, in cross-sectional studies, we utilized only studies reporting optimal cutoffs. In prospective studies, due to a limited number of studies, we utilized optimal cutoffs or cutoffs based on percentiles. In the latter case, percentile cutoff nearest to "standard" cutoffs were selected.

Data extraction
---------------

Data extracted from each eligible study included first author; year of publication; participants' age, sex, and nationality (which was further classified in Asian and non-Asian groups); study type (cross-sectional, prospective); criteria used for defining primary outcomes; and exposure cutoffs. Moreover, we extracted the numbers of patients and healthy individuals for each primary outcome in relation to exposure measures BMI and WHtR, dichotomized according to reported cutoffs. Those numbers were presented in a 2 × 2 table (primary outcome versus exposure) for each outcome and each exposure measure. When precise numbers of patients and healthy individuals depending on exposure measures were not reported in studies presenting optimal exposure cutoffs, we utilized indirect methods for calculating these numbers. Specifically, we used reported sensitivity and specificity rates along with numbers of patients and healthy individuals in order to extract the 2 × 2 table (primary outcome versus exposure).

Quality assessment
------------------

Quality of all selected prospective studies was assessed using the Newcastle-Ottawa quality assessment Scale (NOS).[@b17-dmso-6-403] The NOS uses a star rating system to assess quality based on three aspects of the cohort study: selection of study groups (maximum 4 stars); comparability of study groups (maximum 2 stars); and ascertainment of outcome of interest (maximum 3 stars). Therefore, a prospective study may receive a maximum of 9 stars. The NOS is not able to be used in cross-sectional studies, therefore a similar approach to the one used by Friedemann et al was used.[@b16-dmso-6-403] This approach considered five elements: 1) representativeness of the study; 2) ascertainment of exposure; 3) selective reporting; 4) incomplete outcome data; and 5) assessment of outcome. Each of these outcomes could receive 1 star, therefore a cross-sectional study might receive a maximum of 5 stars.

Statistical analysis
--------------------

Pooled ratio of relative risks (rRR) with 95% CIs was the principal measure for comparing the strength of BMI versus that of WHtR as a screening tool for the primary outcomes. The pooled rRR was calculated as follows:
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and then antilog to construct asymmetric 95% CI around rRR. The variance of log(rRR) was approximated by the sum of the variances of log(RR~BMI~) and log(RR~WHtR~). In most studies, results were reported separately for men and women; therefore, results from these studies were included separately, and thus the term "data units" is used instead of "studies." Meta-analysis of rRR for primary outcomes reported in at least two studies was performed using the DerSimonian and Laird random effect statistical model.[@b18-dmso-6-403] This model takes into account both the between- and within-studies variability.

Subgroup analysis was also performed by first stratifying the studies according to origin (Asian and non-Asian) and then further stratified according to sex. Quantitative heterogeneity in the results was investigated by the I^2^ statistic, while the Egger's regression test was used to assess the publication bias in each obesity measure separately. Investigation of possible sources of heterogeneity was performed using meta-regression in outcomes from the cross-sectional studies. In the outcomes from prospective studies, meta-regression was not performed due to the limited number of studies. The log(rRR) was used as the dependent variable in meta-regression, and participants' sex, origin, optimal BMI or WHtR cutoffs, as well as an interaction term between participants' sex and origin, were used as the covariates in attempts to explain the heterogeneity.

Analyses were performed with the aid of the metafor package[@b19-dmso-6-403] with R statistical software (v 3.0.1; The R Foundation for Statistical Computing, Vienna, Austria).[@b20-dmso-6-403]

Results
=======

Study and participant characteristics
-------------------------------------

The search strategy yielded 1,460 studies from the PubMed database and 763 studies from the Embase database. After applying inclusion and exclusion criteria, a total of 34 studies were included in this meta-analysis ([Figure 1](#f1-dmso-6-403){ref-type="fig"}); 46 data units from 24 cross-sectional studies with optimal BMI and WHtR cutoffs[@b21-dmso-6-403]--[@b44-dmso-6-403] and 18 data units from ten prospective studies.[@b45-dmso-6-403]--[@b54-dmso-6-403] The total number of participants in the cross-sectional studies was 221,814 individuals, of which 177,974 were Asians and 43,840 non-Asians. In the cross-sectional studies, there were 6,850 patients with DM, 26,491 patients with dyslipidemia, 20,467 with elevated blood pressure, and 19,014 with MetS. The total number of participants in the prospective studies was 290,995 individuals of which 137,325 were Asians and 153,670 non-Asians. In prospective studies, there were 6,057 patients with incident DM, 4,388 patients with incident CVD, 1,903 with CVD mortality, and 5,642 with all-cause mortality.

In all 34 studies, the total number of participants was 512,809 persons. The age limit in the inclusion criteria was 18 years or older; however, we included two studies in which participants' ages were \>15 years[@b22-dmso-6-403] or 15 to 74 years.[@b27-dmso-6-403] Furthermore, four of the included studies did not determine range of age but rather provided mean age with standard deviation.[@b25-dmso-6-403],[@b28-dmso-6-403],[@b29-dmso-6-403],[@b34-dmso-6-403]

The characteristics of the included studies are presented in [Table 1](#t1-dmso-6-403){ref-type="table"}. From cross-sectional studies reporting results based on optimal BMI and WHtR cutoffs, we identified a total of 27 data units from 14 studies reporting associations with DM,[@b21-dmso-6-403]--[@b34-dmso-6-403] 19 data units from ten studies with dyslipidemia,21,23--25,27,29,32--35 34 data units from 18 studies with elevated blood pressure,[@b21-dmso-6-403]--[@b25-dmso-6-403],[@b27-dmso-6-403]--[@b32-dmso-6-403],[@b34-dmso-6-403]--[@b40-dmso-6-403] and 16 data units from eight studies with MetS.[@b23-dmso-6-403],[@b33-dmso-6-403],[@b35-dmso-6-403],[@b38-dmso-6-403],[@b41-dmso-6-403]--[@b43-dmso-6-403] In prospective studies, we identified ten data units from five studies reporting associations with incident DM,[@b21-dmso-6-403]--[@b44-dmso-6-403] four data units from three studies with incident CVD,[@b50-dmso-6-403]--[@b52-dmso-6-403] four data units from two studies with CVD mortality,[@b53-dmso-6-403],[@b54-dmso-6-403] and four data units from two studies with all-cause mortality.[@b53-dmso-6-403],[@b54-dmso-6-403]

Exposure measure cutoffs
------------------------

The summary of the optimal cutoffs from the cross-sectional studies in each of the outcomes is presented in [Table 2](#t2-dmso-6-403){ref-type="table"}. From this table, it is obvious that both BMI and WHtR optimal cutoffs were generally higher in non-Asian than in Asian populations. Moreover, medians of WHtR were also generally higher than the suggested cutoff of 0.500 in non-Asian individuals, and this was even the case in three out of four outcomes in Asian populations. Similar data are not presented for prospective studies because in four out of the ten included studies, cutoffs were not optimal but rather based on percentiles. A visual inspection of the cutoffs utilized in each data unit in prospective studies provides the impression that cutoffs are higher in non-Asians compared to Asians regarding incident DM and incident CVD.

Results from cross-sectional studies with optimal cutoffs for BMI and WHtR
--------------------------------------------------------------------------

Primary outcomes from these studies were DM, dyslipidemia, elevated blood pressure, and MetS. Results for DM are presented in [Figure 2](#f2-dmso-6-403){ref-type="fig"}. The overall rRR clearly indicates that WHtR is superior to BMI in detecting DM (rRR: 0.71, 95% CI: 0.59--0.84). The association of WHtR with DM was stronger for both Asians (rRR: 0.64, 95% CI: 0.50--0.83) and non-Asians (rRR: 0.79, 95% CI: 0.63--0.99). Moreover, subgroup analysis indicates that WHtR is also superior to BMI in discriminating DM in both male and female Asians and non-Asian females.

The overall comparison measure for dyslipidemia was in favor of neither of the exposures (rRR: 1.00, 95% CI: 0.87--1.15), as shown in [Figure 3](#f3-dmso-6-403){ref-type="fig"}. However, the comparison measure was statistically significant in favor of WHtR in Asian populations (rRR: 0.92, 95% CI: 0.88--0.96), and this comparison remains statistically significant in favor of WHtR in both male and female Asians. In non-Asians, although the data units from the study of Berber et al[@b21-dmso-6-403] were well in favor of BMI, neither exposure proved superior to the other (rRR: 1.24, 95% CI: 0.84--1.83).

Similar findings were observed for elevated blood pressure, with the overall comparison measure (rRR: 0.95, 95% CI: 0.83--1.11) being in favor of neither of the two exposures ([Figure 4](#f4-dmso-6-403){ref-type="fig"}), although it was in favor of WHtR in Asian populations (rRR: 0.87, 95% CI: 0.77--0.98); however, the comparison measures attenuated within sex in Asians. In non-Asians, the data units from the study of Berber et al[@b21-dmso-6-403] again indicate a significantly stronger association of BMI with elevated blood pressure.

Finally, the overall comparison measure for MetS ([Figure 5](#f5-dmso-6-403){ref-type="fig"}) was in favor of WHtR (rRR: 0.92, 95% CI: 0.89--0.96). This was also true in Asian populations (rRR: 0.92, 95% CI: 0.89--0.96) and in both male and female Asians. However, the two exposures performed equally in non-Asians (rRR: 0.92, 95% CI: 0.81--1.03). The definition of MetS among utilized studies included WC in three out of the eight studies;[@b35-dmso-6-403],[@b38-dmso-6-403],[@b41-dmso-6-403] two out of these three studies comprised non-Asians. Sensitivity analyses were used to explore the degree to which the findings were affected by these three studies. The overall rRR (ie, with ten data units after excluding the three studies) remained statistically significant in favor of WHtR (rRR: 0.93, 95% CI: 0.89--0.97). Similarly, in Asians, after removing the study of Hsu et al[@b35-dmso-6-403] (ie, eight data units), the association remained statistically significant in favor of WHtR (rRR: 0.93, 95% CI: 0.89--0.97). A similar analysis was not performed in non-Asians because of the limited number of studies.

Results from prospective studies
--------------------------------

Associations from available prospective studies are presented in [Figure 6](#f6-dmso-6-403){ref-type="fig"}. The assessed outcomes were incident DM, incident CVD, CVD mortality, and all-cause mortality. Regarding the two mortality outcomes, data were available only from non-Asian populations. Although there were only four data units from only two studies for each mortality outcome, the results were well in favor of WHtR compared to BMI; pooled rRR for CVD mortality was 0.42 (95% CI: 0.35--0.50) and, for all-cause mortality, 0.49 (95% CI: 0.41--0.59). Results were also in favor of WHtR compared to BMI regarding incident CVD in both Asians (rRR: 0.64, 95% CI: 0.57--0.72) and non-Asians (rRR: 0.75, 95% CI: 0.64--0.87). Finally, WHtR was superior in detecting incident DM in Asian populations (rRR: 0.90, 95% CI: 0.81--0.99) but not in non-Asian populations (rRR: 0.91, 95% CI: 0.78--1.05). Due to the small number of data units, within-sex analyses were not performed.

Quality assessment
------------------

Results of quality assessment for the selected studies are presented in [Tables S1](#SD1-dmso-6-403){ref-type="supplementary-material"} and [S2](#SD2-dmso-6-403){ref-type="supplementary-material"}. In prospective studies ([Table S1](#SD1-dmso-6-403){ref-type="supplementary-material"}), eight out of the ten studies received 7 or 8 stars; two studies received lower scores, ie, the study of Jia et al[@b47-dmso-6-403] in Asians and the study of Sargeant et al[@b48-dmso-6-403] in non-Asians, both of which gave data for incident DM. Sensitivity analysis in Asians, excluding the study of Jia et al,[@b47-dmso-6-403] attenuated the association (rRR: 0.84, 95% CI: 0.55--1.27). Sensitivity analysis in non-Asians did not alter the association, which remained in favor of neither of the exposures (rRR: 0.90, 95% CI: 0.73--1.12).

In cross-sectional studies, 22 of the included 24 studies received 4 or 5 stars out of the maximum 5. Two studies scored 3 stars -- the study of Berber et al[@b21-dmso-6-403] in non-Asians and the study of Tseng et al[@b34-dmso-6-403] in Asians. Both studies gave data for the outcomes of DM, elevated blood pressure, and dyslipidemia. Sensitivity analysis, excluding results from the study of Tseng et al in Asians,[@b34-dmso-6-403] did not alter the findings. In non-Asians, excluding the study of Berber et al[@b21-dmso-6-403] did not alter the association for DM, which remained in favor of WHtR; however, it resulted in statistically significant associations in favor of WHtR regarding elevated blood pressure (rRR: 0.87, 95% CI: 0.79--0.96) and dyslipidemia (rRR: 0.92, 95% CI: 0.86--0.99).

Heterogeneity and publication biases
------------------------------------

A substantial heterogeneity among the results was observed in those outcomes having low uncertainty in I^2^ ([Table 3](#t3-dmso-6-403){ref-type="table"}). The low uncertainty in I^2^ is indicated by the relatively small range of its 95% CI. This substantial heterogeneity is not surprising, given the observed differences between Asians and non-Asians. When there was a high uncertainty in I^2^, then no safe conclusions could be made about the heterogeneity of the results. We further explored between-study heterogeneity by meta-regression analysis for the predefined study-level covariates in outcomes from the cross-sectional studies ([Table S3](#SD3-dmso-6-403){ref-type="supplementary-material"}). None of these covariates has a significant relationship with the log of RR and, therefore, they cannot help in explaining the heterogeneity between the studies.

Regarding publication bias, Egger's regression tests imply that there is asymmetry in the funnel plots regarding DM in cross-sectional studies for both BMI and WHtR, both overall and in Asians. There was also an indication for asymmetry in the funnel plot regarding CVD mortality in BMI studies. In the remaining outcomes, there was no indication of possible publication bias.

Discussion
==========

Summary of evidence
-------------------

This meta-analysis was based on 34 studies, of which 24 were cross-sectional and ten prospective, with more than 500,000 participants. The results demonstrate that the pooled rRR of BMI to WHtR was in favor of WHtR in detecting DM, dyslipidemia, elevated blood pressure, and MetS in Asian populations and DM in non-Asian populations in cross-sectional studies. At this point, it should be noted that, in non-Asian populations, as far as dyslipidemia and elevated blood pressure are concerned, data from the study of Berber et al[@b21-dmso-6-403] appear to be extremely in favor of BMI. However, the quality assessment of this study was rather poor, and when we removed these data units from the analysis, the pooled rRR proved also in favor of WHtR in both outcomes. WHtR was also superior to BMI in detecting incident DM and incident CVD in Asian populations and incident CVD, CVD mortality, and all-cause mortality in non-Asian populations in prospective studies. Regarding CVD mortality and all-cause mortality outcomes, it should be noted that data were available only from non-Asian populations. The performance of rRR was generally similar in male and female participants in cross-sectional studies, whereas sex-specific analysis was not performed in prospective studies because of the limited number of data units. BMI did not prove superior to WHtR in any of the evaluated outcomes when all data units were analyzed, or within ethnicity and sex subgroup analysis.

Considerations about this meta-analysis
---------------------------------------

To the best of our knowledge, this is the first meta-analysis that has examined the pooled rRR of BMI to WHtR in detecting cardiometabolic outcomes using optimal cutoffs of the two exposure measures. The superiority of WHtR compared to BMI in certain cardiometabolic outcomes documented in our meta-analysis is in line with other meta-analyses that demonstrated that WHtR is superior to BMI in detecting several cardiometabolic risk factors[@b12-dmso-6-403] and, particularly, DM.[@b14-dmso-6-403] On the other hand, two other meta-analyses did not provide evidence that WHtR was superior to BMI or that BMI was superior to WHtR in detecting cardiometabolic risk.[@b13-dmso-6-403],[@b15-dmso-6-403]

Obesity remains a huge challenge globally, because it is one of the most important causes of premature death. In an effort to optimize identification of high-risk individuals, new indices are proposed, such as the Body Shape Index.[@b55-dmso-6-403] There are, however, several reasons why WHtR has been proposed as a useful single global index to determine health risks.[@b10-dmso-6-403] The results from the present and other meta-analyses, when taken together, may justify the use of WHtR or other abdominal obesity proxy measures as a single screening tool for cardiometabolic risk rather than BMI. This may be justified given the low sensitivity of BMI in detecting excess body fat[@b56-dmso-6-403] and metabolic risk[@b57-dmso-6-403] and because of the "J"-shape association of BMI with cardiovascular risk stratification.[@b56-dmso-6-403] Compared to WC, which is currently the most widely used index of abdominal obesity, WHtR is thought to be better in discriminating cardiometabolic risk because it takes into account height, which is important particularly in shorter individuals.[@b58-dmso-6-403]

One of the proposed advantages in using WHtR instead of BMI is the ability to use one single cutoff point (0.5) in all ages, both sexes, and all ethnicities.[@b11-dmso-6-403],[@b57-dmso-6-403],[@b59-dmso-6-403] This provides a simple public health message: "Keep your waist circumference to less than half your height."[@b11-dmso-6-403] However, it should be noted that our results from cross-sectional studies indicated that the optimal cutoff of WHtR was substantially higher than the simple cutoff of 0.5, particularly in non-Asians. Therefore, we may argue that the use of this single cutoff point is not justified with the results of the present meta-analysis and that further evidence is warranted to clarify this issue.

One of the issues pertaining to WHtR is the point of WC measurement. It has been suggested that measuring WC at the level of umbilicus rather than at the narrowest point between the lower costal border and the top of the iliac crest improves sensitivity in detecting percent excess fat, particularly in women.[@b60-dmso-6-403] On the other hand, Ashwell and Browning have suggested measuring WC midway between the lower rib and iliac crest simply because this was the most often-used measurement they found in a review and because this was the preferred site of measurement recommended by the World Health Organization (WHO).[@b61-dmso-6-403]

Limitations
-----------

The main advantage of a meta-analysis is the calculation of effect sizes with more precision compared to data of a single study. Although we aimed to choose specific and robust cutoffs for the definition of the utilized outcomes for this meta-analysis, outcome-specific bias cannot be excluded due to the combination of data from different studies in which different definitions for each outcome were used. Furthermore, as far as certain outcomes are concerned, the number of available studies was limited. There were only three studies for dyslipidemia and MetS in non-Asians, three studies for incident CVD, and just two studies for CVD and all-cause mortality.

The small number of included studies for certain outcomes in non-Asians prevented us from further evaluating the discriminating ability of BMI and WHtR within non-Asian subpopulations, such as Caucasians, blacks, and so on. This would be an important task given the current WHO recommendation of using a single BMI cutoff for non-Asians, but also on the suggestion of using a single cutoff of WHtR in evaluating cardiometabolic risk.[@b11-dmso-6-403]

In this meta-analysis, participants belonging to any ethnicity were included. Therefore, we opted to use studies reporting results based on optimal cutoffs for the exposure indices rather than the "standard" cutoffs (eg, WHtR 0.5, BMI 23 kg/m^2^ in Asians or 25 kg/m^2^ in non-Asians). However, in prospective studies, we included studies irrespective of selection of exposure cutoffs because of the limited number of data units in certain outcomes. Another issue with prospective studies is the unknown effect of follow-up duration (ranges from 2 to 17 years) on the estimated effect size.

In the present meta-analysis, we opted to compare the discriminative analysis of BMI, which is an index of general adiposity, with WHtR, an index of abdominal adiposity, in detecting cardiometabolic risk for those reasons already mentioned. However, it should be underlined that other indices measuring abdominal adiposity have been also found to be superior to BMI. Although Ashwell et al[@b12-dmso-6-403] have demonstrated that WHtR is superior to WC in detecting cardiometabolic risk, more research may be needed to document this superiority.

Publication bias might account for some of the observed effect sizes regarding DM in cross-sectional studies and CVD mortality. Moreover, the results of this meta-analysis should be interpreted cautiously because of the presence of heterogeneity in some of the outcomes and the high uncertainty about I^2^ statistics in other outcomes. Meta-regression showed that none of the predefined covariates could explain part of the heterogeneity between the studies in the outcomes regarding DM, elevated blood pressure, dyslipidemia, and MetS in cross-sectional studies.

Conclusion
==========

This meta-analysis provides evidence that WHtR is superior to BMI in detecting several cardiometabolic risk factors, both in cross-sectional and prospective studies. Despite the heterogeneity of results among studies and evidence of asymmetry in some of the outcomes, it is important to emphasize that BMI was not superior to WHtR in detecting any of the evaluated outcomes in this study, and thus we conclude that WHtR can be used as a screening tool for cardiometabolic risk at least as efficiently as BMI in both Asian and non-Asian populations.

Supplementary tables
====================

###### 

Quality assessment of prospective studies based on the Newcastle-Ottawa scale

  Prospective study                       Selection   Comparability   Outcome   Total stars                            
  --------------------------------------- ----------- --------------- --------- ------------- ---- ---- ---- ---- ---- ---
  Aekplakorn et al[@b50-dmso-6-403]       \*          \*              \*        --            \*   --   \*   \*   \*   7
  Chei et al[@b45-dmso-6-403]             \*          \*              \*        \*            \*   \*   \*   \*   --   8
  Gelber et al[@b51-dmso-6-403]           --          \*              \*        \*            \*   --   \*   --   --   5
  Huerta et al[@b46-dmso-6-403]           \*          \*              \*        \*            \*   --   \*   --   --   6
  Jia et al[@b47-dmso-6-403]              \*          \*              \*        \*            \*   \*   \*   --   \*   8
  Petursson et al[@b53-dmso-6-403]        --          \*              \*        \*            \*   \*   \*   \*   \*   8
  Sargeant et al[@b48-dmso-6-403]         --          \*              --        \*            \*   \*   \*   \*   \*   7
  Welborn and Dhaliwal[@b54-dmso-6-403]   \*          \*              \*        \*            \*   --   \*   \*   \*   8
  Xu et al[@b49-dmso-6-403]               \*          \*              \*        \*            \*   --   \*   \*   \*   8
  Zhang et al[@b52-dmso-6-403]            \*          \*              \*        \*            \*   --   \*   \*   --   7

**Notes:** 1: Representativeness of the exposed cohort; 2: selection of the non-exposed cohort; 3: ascertainment of exposure; 4: demonstration that outcome of interest was not present at start of study; 5: comparability of cohorts on the basis of the design or analysis; 6: comparability of cohorts on the basis of the design or analysis; 7: assessment of outcome; 8: was follow-up long enough for outcomes to occur; 9: adequacy of follow-up of cohorts. More information available from: <http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>.[@b17-dmso-6-403]

###### 

Quality assessment of cross-sectional studies

  Cross-sectional study                     Representative sample   Ascertainment of exposure   Selective reporting   Incomplete outcome data   Assessment of outcome   Total score (maximum 5)
  ----------------------------------------- ----------------------- --------------------------- --------------------- ------------------------- ----------------------- -------------------------
  Al-Odat et al[@b40-dmso-6-403]            --                      \*                          \*                    \*                        \*                      4
  Berber et al[@b21-dmso-6-403]             --                      \*                          \*                    --                        \*                      3
  Craig et al[@b22-dmso-6-403]              \*                      \*                          \*                    \*                        \*                      5
  Deshmukh et al[@b36-dmso-6-403]           \*                      \*                          \*                    --                        \*                      4
  Dong et al[@b23-dmso-6-403]               \*                      \*                          \*                    \*                        \*                      5
  He et al[@b42-dmso-6-403]                 --                      \*                          \*                    \*                        \*                      4
  Ho et al[@b24-dmso-6-403]                 --                      \*                          \*                    \*                        \*                      4
  Hsu et al[@b35-dmso-6-403]                \*                      \*                          \*                    \*                        \*                      5
  Khader et al[@b37-dmso-6-403]             \*                      \*                          \*                    \*                        \*                      5
  Ko et al[@b25-dmso-6-403]                 --                      \*                          \*                    \*                        \*                      4
  Li et al[@b26-dmso-6-403]                 \*                      \*                          \*                    \*                        \*                      5
  Li and McDermott[@b27-dmso-6-403]         --                      \*                          \*                    \*                        \*                      4
  Li et al[@b28-dmso-6-403]                 --                      \*                          \*                    \*                        \*                      4
  Lin et al[@b29-dmso-6-403]                --                      \*                          \*                    \*                        \*                      4
  Mansour and Al-Jazairi[@b30-dmso-6-403]   \*                      \*                          \*                    \*                        \*                      5
  Nakamura et al[@b43-dmso-6-403]           --                      \*                          \*                    \*                        \*                      4
  Park et al[@b31-dmso-6-403]               --                      \*                          \*                    \*                        \*                      4
  Pua and Ong[@b32-dmso-6-403]              --                      \*                          \*                    \*                        \*                      4
  Rodrigues et al[@b38-dmso-6-403]          --                      \*                          \*                    \*                        \*                      4
  Schneider et al[@b33-dmso-6-403]          --                      \*                          \*                    \*                        \*                      4
  Silva et al[@b39-dmso-6-403]              \*                      \*                          \*                    \*                        \*                      5
  Singh et al[@b40-dmso-6-403]              --                      \*                          \*                    \*                        \*                      4
  Tseng et al[@b34-dmso-6-403]              --                      \*                          \*                    --                        \*                      3
  Wakabayashi and Daimon[@b44-dmso-6-403]   --                      \*                          \*                    \*                        \*                      4

###### 

Random effects meta-regression analysis for cross-sectional studies using predefined study covariates

                            Estimated coefficients (95% CI)[\*](#tfn5-dmso-6-403){ref-type="table-fn"} for covariates used in multivariable meta-regression analysis                                                                      
  ------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ --------------------- --------------------- ---------------------- ---------------------
  Diabetes mellitus         0.33 (−3.69, 4.70)                                                                                                                         0.17 (−0.34, 0.68)    0.05 (−0.10, 0.21)    −4.63 (−16.54, 7.28)   −0.07 (−0.84, 0.70)
  Dyslipidemia              0.55 (−0.05, 1.16)                                                                                                                         0.10 (−0.24, 0.44)    0.03 (−0.19, 0.24)    −4.20 (−12.09, 3.69)   −0.08 (−0.69, 0.53)
  Elevated blood pressure   0.28 (−0.18, 0.74)                                                                                                                         −0.01 (−0.43, 0.42)   −0.01 (−0.12, 0.12)   −1.42 (−7.59, 4.75)    −0.02 (−0.75, 0.70)
  Metabolic syndrome        0.01 (−0.29, 0.29)                                                                                                                         0.05 (−0.08, 0.18)    −0.03 (−0.10, 0.04)   1.66 (−2.36, 5.69)     −0.02 (−0.31, 0.27)

**Note:**

None of the estimated coefficients reached statistical significance (all *P*\>0.05).

**Abbreviations:** BMI, body mass index; CI, confidence interval; WHtR, waist-to-height ratio.

The authors are grateful to George Kafatos for his critical comments on the manuscript draft. They are also grateful to Nanette Christou for her valuable help in the preparation of the manuscript.
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![Forest plot for discrimination of diabetes mellitus in cross-sectional studies with optimal BMI and WHtR cutoffs.\
**Abbreviations:** BMI, body mass index; CI, confidence interval; RE, random effects; WHtR, waist-to-height ratio.](dmso-6-403Fig2){#f2-dmso-6-403}

![Forest plot for discrimination of dyslipidemia in cross-sectional studies with optimal BMI and WHtR cutoffs.\
**Abbreviations:** BMI, body mass index; CI, confidence interval; RE, random effects; WHtR, waist-to-height ratio.](dmso-6-403Fig3){#f3-dmso-6-403}

![Forest plot for discrimination of elevated blood pressure in cross-sectional studies with optimal BMI and WHtR cutoffs.\
**Abbreviations:** BMI, body mass index; CI, confidence interval; RE, random effects; WHtR, waist-to-height ratio.](dmso-6-403Fig4){#f4-dmso-6-403}

![Forest plot for discrimination of metabolic syndrome in cross-sectional studies with optimal BMI and WHtR cutoffs.\
**Abbreviations:** BMI, body mass index; CI, confidence interval; RE, random effects; WHtR, waist-to-height ratio.](dmso-6-403Fig5){#f5-dmso-6-403}

![Forest plot for discrimination of incident diabetes mellitus, incident CVD, CVD mortality, and all-cause mortality in prospective studies with BMI and WHtR.\
**Abbreviations:** BMI, body mass index; CI, confidence interval; CVD, cardiovascular disease; RE, random effects; WHtR, waist-to-height ratio.](dmso-6-403Fig6){#f6-dmso-6-403}

###### 

Characteristics of included studies

  Author                                             Ethnicity               Ethnic group   Sex    Number of participants   Age range or mean age ± SD (years)   BMI and WHtR cutoff selection   Outcome
  -------------------------------------------------- ----------------------- -------------- ------ ------------------------ ------------------------------------ ------------------------------- --------------------------------------
  **Cross-sectional studies with optimal cutoffs**                                                                                                                                               
  Al-Odat et al[@b41-dmso-6-403]                     Jordanian               Non-Asian      M, F   212; 288                 20--85                               Optimal                         MetS
  Berber et al[@b21-dmso-6-403]                      Mexican                 Non-Asian      M, F   2,426; 5,939             \>20                                 Optimal                         DM, Dys, EBP
  Craig et al[@b22-dmso-6-403]                       Tongan                  Non-Asian      M, F   314; 453                 \>15                                 Optimal                         DM, EBP
  Deshmukh et al[@b36-dmso-6-403]                    Indian                  Asian          M, F   1,059; 1,641             \>18                                 Optimal                         EBP
  Dong et al[@b23-dmso-6-403]                        Chinese                 Asian          M, F   1,522; 1,484             20--74                               Optimal                         DM, Dys, EBP, MetS
  He et al[@b42-dmso-6-403]                          Chinese                 Asian          M, F   430; 638                 \>40                                 Optimal                         MetS
  Ho et al[@b24-dmso-6-403]                          Hong Kong Chinese       Asian          M, F   1,412; 1,483             27--74                               Optimal                         DM, Dys, EBP
  Hsu et al[@b35-dmso-6-403]                         Taiwanese               Asian          M, F   1,147; 1,212             40--94                               Optimal                         Dys, EBP, MetS
  Khader et al[@b37-dmso-6-403]                      Jordanian               Non-Asian      M, F   1,128; 3,462             \>18                                 Optimal                         EBP
  Ko et al[@b25-dmso-6-403]                          Hong Kong Chinese       Asian          M, F   910; 603                 36.6 ± 9.2                           Optimal                         DM, Dys, EBP
  Li et al[@b26-dmso-6-403]                          US                      Non-Asian      M, F   2,994; 3,283             \>20                                 Optimal                         DM
  Li and McDermott[@b27-dmso-6-403]                  Australian Aboriginal   Non-Asian      M, F   760; 881                 15--74                               Optimal                         DM, Dys, EBP
  Li et al[@b28-dmso-6-403]                          Taiwanese               Asian          M, F   21,038; 15,604           37.2 ± 9.4                           Optimal                         DM, EBP
  Lin et al[@b29-dmso-6-403]                         Chinese                 Asian          M, F   26,359; 29,204           37.3 ± 10.9                          Optimal                         DM, Dys, EBP
  Mansour and Al-Jazairi[@b30-dmso-6-403]            Iraqi                   Non-Asian      M, F   6,693; 6,293             \>18                                 Optimal                         DM, EBP
  Nakamura et al[@b43-dmso-6-403]                    Japanese                Asian          M, F   330; 514                 40--69                               Optimal                         MetS
  Park et al[@b31-dmso-6-403]                        Korean                  Asian          M, F   2,327; 3,102             \>20                                 Optimal                         DM, EBP
  Pua and Ong[@b32-dmso-6-403]                       Singaporean             Asian          F      566                      18--68                               Optimal                         DM, Dys, EBP
  Rodrigues et al[@b38-dmso-6-403]                   Brazilian               Non-Asian      M, F   759; 896                 25--64                               Optimal                         EBP, MetS
  Schneider et al[@b33-dmso-6-403]                   German                  Non-Asian      M, F   2,016; 3,361             20--79                               Optimal                         DM, Dys, MetS
  Silva et al[@b39-dmso-6-403]                       Brazilian               Non-Asian      M, F   754; 928                 20--59                               Optimal                         EBP
  Singh et al[@b40-dmso-6-403]                       Indian                  Asian          M, F   3,118                    \>30                                 Optimal                         EBP
  Tseng et al[@b34-dmso-6-403]                       Taiwanese               Asian          M, F   2,280; 2,403             44.5 ± 11.9                          Optimal                         DM, Dys, EBP
  Wakabayashi and Daimon[@b44-dmso-6-403]            Japanese                Asian          M, F   37,697; 19,891           35--70                               Optimal                         MetS
  **Prospective studies**                                                                                                                                                                        
  Aekplakorn et al[@b50-dmso-6-403]                  Thai                    Asian          M      2,536                    35--59                               Optimal                         Incident CVD
  Chei et al[@b45-dmso-6-403]                        Japanese                Asian          M, F   974; 1,998               40--69                               Percentiles                     Incident DM
  Gelber et al[@b51-dmso-6-403]                      US                      Non-Asian      M, F   16,332; 32,700           40--84; ≥45                          Percentiles                     Incident CVD
  Huerta et al[@b46-dmso-6-403]                      Spanish                 Non-Asian      M, F   14,019; 23,714           30--65                               Optimal                         Incident DM
  Jia et al[@b47-dmso-6-403]                         Chinese                 Asian          M, F   48,015; 13,688           18--85                               Optimal                         Incident DM
  Petursson et al[@b53-dmso-6-403]                   Norwegian               Non-Asian      M, F   26,461; 30,510           20--79                               Percentiles                     All-cause mortality, CVD mortality
  Sargeant et al[@b48-dmso-6-403]                    Jamaican                Non-Asian      M, F   290; 438                 25--74                               Optimal                         Incident DM
  Welborn and Dhaliwal[@b54-dmso-6-403]              Australian              Non-Asian      M, F   4,508; 4,698             20--69                               Optimal                         All-cause mortality, n CVD mortality
  Xu et al[@b49-dmso-6-403]                          Chinese                 Asian          M, F   1,384; 1,647             \>35                                 Optimal                         Incident DM
  Zhang et al[@b52-dmso-6-403]                       Chinese                 Asian          F      67,083                   40--70                               Percentiles                     Incident CVD

**Abbreviations:** BMI, body mass index; CVD, cardiovascular disease; DM, diabetes mellitus; Dys, dyslipidemia; EBP, elevated blood pressure; MetS, metabolic syndrome; SD, standard deviation; WHtR, waist-to-height ratio.

###### 

Summary of optimal exposure cutoffs from cross-sectional studies

  Outcome                     Asians   Non-Asians                  
  --------------------------- -------- ---------------------- ---- ----------------------
  Waist-to-height ratio                                            
   Diabetes mellitus          15       0.510 (0.480, 0.530)   12   0.560 (0.500, 0.620)
   Dyslipidemia               13       0.480 (0.450, 0.520)   6    0.526 (0.500, 0.600)
   Elevated blood pressure    20       0.510 (0.450, 0.530)   14   0.528 (0.490, 0.600)
   Metabolic syndrome         10       0.520 (0.500, 0.540)   6    0.550 (0.530, 0.610)
  Body mass index (kg/m^2^)                                        
   Diabetes mellitus          15       24.3 (23.2, 25.5)      12   26.1 (23.8, 35.0)
   Dyslipidemia               13       23.7 (22.1, 25.0)      6    25.2 (23.9, 26.8)
   Elevated blood pressure    20       24.1 (21.2, 26.3)      14   26.2 (23.6, 31.7)
   Metabolic syndrome         10       24.3 (22.6, 26.0)      6    26.7 (25.8, 30.3)

###### 

Study heterogeneity and publication biases

  Outcome, origin              Study type        Number of data units   I^2^ (95% CI)       Asymmetry test[\*](#tfn2-dmso-6-403){ref-type="table-fn"} (*z* statistic)   
  ---------------------------- ----------------- ---------------------- ------------------- --------------------------------------------------------------------------- --------------------------------------------------
  Diabetes mellitus            Cross-sectional                                                                                                                          
   All                                           27                     78.8 (60.7, 87.6)   2.439[\*](#tfn2-dmso-6-403){ref-type="table-fn"}                            2.163[\*](#tfn2-dmso-6-403){ref-type="table-fn"}
   Asians                                        15                     74.4 (47.7, 88.2)   2.078[\*](#tfn2-dmso-6-403){ref-type="table-fn"}                            1.865[\*](#tfn2-dmso-6-403){ref-type="table-fn"}
   Non-Asians                                    12                     79.3 (52.4, 92.5)   0.980                                                                       0.809
  Dyslipidemia                 Cross-sectional                                                                                                                          
   All                                           19                     96.2 (93.2, 98.3)   0.383                                                                       1.247
   Asians                                        13                     39.5 (0, 75.7)      0.206                                                                       0.527
   Non-Asians                                    6                      98.2 (95.3, 99.7)   0.384                                                                       1.549
  Elevated blood pressure      Cross-sectional                                                                                                                          
   All                                           34                     92.5 (87.7, 95.6)   1.150                                                                       1.651
   Asians                                        20                     80.0 (61.7, 92.4)   1.694                                                                       1.680
   Non-Asians                                    14                     95.3 (90.7, 98.1)   −1.466                                                                      −0.316
  Metabolic syndrome           Cross-sectional                                                                                                                          
   All                                           16                     0 (0, 67.3)         1.089                                                                       0.069
   Asians                                        10                     0.02 (0, 92.4)      1.236                                                                       0.102
   Non-Asians                                    6                      0 (NA)              −0.037                                                                      −0.044
  Incident diabetes mellitus   Prospective                                                                                                                              
   Asians                                        6                      0.1 (0, 95.7)       −1.322                                                                      −1.353
   Non-Asians                                    4                      18.2 (1.0, 92.8)    0.214                                                                       0.378
  Incident CVD                 Prospective                                                                                                                              
   Asians                                        2                      0 (0, 99.8)         NA                                                                          NA
   Non-Asians                                    2                      0 (0, 98.3)         NA                                                                          NA
  CVD mortality                Prospective                                                                                                                              
   Non-Asians                                    4                      17.8 (0, 93.1)      2.173[\*](#tfn2-dmso-6-403){ref-type="table-fn"}                            1.229
  All-cause mortality          Prospective                                                                                                                              
   Non-Asians                                    4                      71.3 (12.1, 98.1)   1.285                                                                       0.525

**Note:**

*P*-value for *z* statistic \<0.05.

**Abbreviations:** BMI, body mass index; CI, confidence interval; CVD, cardiovascular disease; NA, not applicable; WHtR, waist-to-height ratio.
